AB Science announced the recruitment of the first patient in its Phase 3 study evaluating masitinib for severe persistent asthma. This is an international, multicenter, randomized, double-blind, placebo-controlled, 2-parallel groups, study to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the treatment of patients with Severe Persistent Asthma treated with oral corticosteroids.
Masitinib is an orally administered tyrosine kinase inhibitor that targets mast cells, important cells for immunity, as well as a limited number of kinases that play key roles in various cancers. Through its activity on the mast cell and certain kinases essential to the activation of the inflammatory cells and fibrosing tissue remodelling, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases.
For more information call (973) 218-2437 or visit www.ab-science.com.